Note: This Sole Source Certification will become a public document, open to public inspection; therefore, you should be certain all material facts are true, relevant and clearly understandable.

SOLE SOURCE CERTIFICATION

Under the requirement of University of Florida Rule No. 6C1-3.020(5)(f)(2), the following is submitted in support of this request for authority to purchase, without bidding, the items available from only one source.

Note: Sole Source means that the item/service is unique and that the vendor is the only one from whom the item/service can be provided. Best Price alone cannot be used for sole source. If the item/service is available from more than one source of supply, best price must be determined through the competitive bid process.

A. Sole Source Vendor Company Name: Kenya Veterinary Vaccines Production Institute (KEVEVAPI)

Contact Person: Dr. Jane Wachira - Chief Executive Officer
Address: Embakasi Off Enterprise Road, Road A, Nairobi, Kenya
Telephone: +251 20 3540166 Fax: __________________ Email: jane.wachira@kevevapi.org

B. Describe in lay language, what the item/service is and how it is to be used in your area of research. (cont. P2)

Production of a vaccine (about 1,000,000 doses) against a disease in sheep and goats commonly referred to as "Peste des Petits Ruminants" (PPR) that can survive for up to one month outside the cold chain (fridge). The vaccine should follow the Thermovac production protocol (open access) and should be tested and validated by the Pan African Veterinary Vaccine Centre (PANVAC). The research will use the vaccine to test innovative vaccine delivery mechanisms in Uganda and Kenya under USAID-funded associate award to the Feed the Future Innovation Lab for Livestock Systems.

C. What feature or special condition of the commodity/service is unique and cannot be obtained from any other source? (cont. P2)

The thermostability of the vaccine is unique as the current conventional PPR vaccine in the market will stop working after 2 or 3 days outside a cold chain (fridge). The current vaccines are therefore of limited use in rural settings in Uganda and Kenya as breakdowns in or unavailability of the cold chain are very common. KEVEVAPI as a research vaccine production institute is uniquely positioned in the region to supply the UF project with required the quantity of vaccines. KEVEVAPI already produces conventional PPR vaccine and has technical and scientific capability to modify production process to produce Thermostable PPR vaccine for project needs.

D. Is this product being purchased directly from the manufacturer?  X Yes  No
If No, is it available from more than one dealer?  X Yes  No
If Yes, it is available from more than one dealer, why can this item not be bid? (cont. P2)

This item cannot be bid because thermostable PPR vaccine is not yet commercially available for purchase nor is it produced by vaccine suppliers globally. The vaccine is not produced in the USA because the Americas are free of the disease and production of PPR vaccine is not permitted under USDA regulations. We reached out to conventional PPR vaccine producers (outside of USA) such as Hester who indicated that their thermostable PPR vaccine is still under development and therefore not yet commercially available. Hester also indicated that they cannot produce one. Another company which was initially included in our proposal to USAID, Botswana Vaccine Institute, withdrew their interest in the production of the thermostable vaccine.

E. Prior to submitting this requisition, did you investigate other possible sources?  X Yes  No
If Yes: 1) Did you obtain quotes from the other sources?  X Yes  No If Yes, attach copies.
2) Is this Vendor’s price lower than the other sources?  X Yes  No If No, justify the additional cost below.

Yes, we investigated other sources for vaccine supply. As indicated above in D, there is no production of thermostable vaccine in the USA and the only company which was potentially capable in India indicated that they can’t do it. The only company that agreed to the production per the required specifications is KEVEVAPI which is capable of producing the thermovac vaccine due to prior experience with thermostable Rinderpest vaccine production.

F. Other Sole Source comments or explanations. (cont. P2)

I / We, the undersigned, certify the above to be true and correct to the best of my / our knowledge and belief and the user and / or undersigned does not have a financial interest in the above named vendor.

DEPARTMENT APPROVAL

I hereby certify the validity of the information and feel confident the Sole Source Certification will meet University criteria and would withstand any audit or vendor protest.

Principal Investigator’s Signature __________________________ Date 11/27/2017

PURCHASING APPROVAL

This acquisition is approved as a non-competitive purchase.

Purchasing Coordinator Signature __________________________ Date 11-28-17

Purchasing Authorized Signature __________________________ Date 11-28-17

FA-PDS-SOLSRC 02/2009
Sole Source Certification (Continued)
Please use the following sections to continue documentation if needed.

B. continued

C. continued
In the past, KEVEVAI participated in the Rinderpest (cattle plague) disease eradication campaign in Kenya and successfully produced thermostable Rinderpest vaccine. The production of PPR thermostable vaccine is similar in process and therefore, KEVEVAI has technical and administrative capability to produce and deliver the required vaccine for LSIL/PPR project.

D. continued

E. continued

F. continued